• DAPA-HF: Dapagliflozin improves worsening HF, CV death similarly in men, women

    1 month ago - By Healio

    Dapagliflozin is equally as effective in women as in men in reducing risk for worsening HF, CV death and all-cause death compared with placebo, according to new data from the DAPA-HF trial.
    “Dapagliflozin reduced the risk of worsening heart failure and death and improved symptoms, physical function and health-related quality of life similarly in men and women with heart failure and reduced ejection fraction,” Jawad H. Butt, MD, research fellow in the department of cardiology at Rigshospitalet at Copenhagen University Hospital in Denmark, and colleagues wrote.
    As Healio previously
    Read more ...